Ezurpimtrostat, A Palmitoyl-Protein Thioesterase-1 Inhibitor, Combined with PD-1 Inhibition Provides CD8+ Lymphocyte Repopulation in Hepatocellular Carcinoma
ConclusionsEzurpimtrostat turns cold tumors into hot tumors and, thus, could improve T cell-mediated immunotherapies in liver cancer.Graphical Abstract (Source: Targeted Oncology)
Source: Targeted Oncology - December 22, 2023 Category: Cancer & Oncology Source Type: research
Efficacy and Safety of Lu-177 DOTATATE Peptide Receptor Radionuclide Therapy in Patients with Unresectable or Metastatic Neuroendocrine Tumors in Korea
ConclusionsIn Korean patients with advanced NETs, Lu-177 DOTATATE PRRT showed efficacy and safety outcomes, consistent with those in the NETTER-1 trial and previous Western real-world studies. (Source: Targeted Oncology)
Source: Targeted Oncology - December 18, 2023 Category: Cancer & Oncology Source Type: research
Correction to: Hematological Toxicity of PARP Inhibitors in Metastatic Prostate Cancer Patients with Mutations of BRCA or HRR Genes: A Systematic Review and Safety Meta-analysis
(Source: Targeted Oncology)
Source: Targeted Oncology - December 9, 2023 Category: Cancer & Oncology Source Type: research
Correction to: EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non ‑Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast
(Source: Targeted Oncology)
Source: Targeted Oncology - December 9, 2023 Category: Cancer & Oncology Source Type: research
Malignant Pleural Mesothelioma: Staging and Radiological Response Criteria in Patients Treated with Immune Checkpoint Inhibitors
AbstractMalignant pleural mesothelioma (MPM) is a rare and challenging cancer associated with asbestos fiber exposure, which offers limited treatment options. Historically, platinum-based chemotherapy has been the primary approach, but recent developments have introduced immunotherapy as a promising alternative for the treatment of this disease. Nevertheless, the unique growth patterns and occasionally ambiguous progressive characteristics of MPM make the interpretation of radiological assessments complex. Immunotherapy further complicates matters by introducing unconventional treatment response patterns such as hyperprogr...
Source: Targeted Oncology - December 8, 2023 Category: Cancer & Oncology Source Type: research
A Novel Prognostic Model Using Pan-Immune-Inflammation Value and Programmed Death Ligand 1 in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Receiving Immune Checkpoint Inhibitors: A Retrospective Multicenter Analysis
ConclusionsPIV is a prognostic biomarker in patients with R/M HNSCC treated with ICI. A prognostic model using PIV and PD-L1 could provide outcome prediction and risk stratification. (Source: Targeted Oncology)
Source: Targeted Oncology - December 2, 2023 Category: Cancer & Oncology Source Type: research
Correction to: Durvalumab: A Review in Advanced Biliary Tract Cancer
(Source: Targeted Oncology)
Source: Targeted Oncology - November 29, 2023 Category: Cancer & Oncology Source Type: research
Hematological Toxicity of PARP Inhibitors in Metastatic Prostate Cancer Patients with Mutations of BRCA or HRR Genes: A Systematic Review and Safety Meta-analysis
ConclusionsIn mCRPC, PARPis increase the risk of hematological toxicity compared with other treatments, both as single agents or combined with ARTA (high-quality evidence). Clinicians should be aware of this risk and the correct management, especially with the expected increased PARPis use in mCRPC. (Source: Targeted Oncology)
Source: Targeted Oncology - November 22, 2023 Category: Cancer & Oncology Source Type: research
Clinical Characteristics of Patients with Advanced ALK-Translocated Non-small Cell Lung Cancers and Long-Term Responses to Crizotinib (CRIZOLONG GFPC 05-19 Study)
ConclusionsMostALK+ aNSCLC patients with prolonged crizotinib efficacy had paucisymptomatic and oligometastatic disease without BMs. They subsequently benefited from a sequential strategy with other ALK-TKIs. (Source: Targeted Oncology)
Source: Targeted Oncology - November 15, 2023 Category: Cancer & Oncology Source Type: research
Impact of Immunotherapy on Real-World Survival Outcomes in Metastatic Renal Cell Carcinoma
ConclusionIn real-world patients with mRCC, immunotherapy is associated with significant survival benefit. The present retrospective analysis shows the real-world benefit of second-line immunotherapy in patients previously treated with tyrosine –kinase inhibitors. (Source: Targeted Oncology)
Source: Targeted Oncology - November 13, 2023 Category: Cancer & Oncology Source Type: research
Durvalumab: A Review in Advanced Biliary Tract Cancer
AbstractDurvalumab (Imfinzi®), a therapeutic human monoclonal antibody which binds to and blocks the activity of the immunosuppressive programmed death-ligand 1 (PD-L1) protein, is approved in the USA, EU, Japan and other countries in combination with gemcitabine and cisplatin for adults with advanced biliary tract cancer. In the pivotal phase 3 TOPAZ-1 trial, durvalumab plus gemcitabine and cisplatin significantly prolonged overall survival and progression-free survival compared with placebo plus gemcitabine and cisplatin in adults with advanced biliary tract cancer. Benefit from durvalumab was seen irrespective of prima...
Source: Targeted Oncology - November 9, 2023 Category: Cancer & Oncology Source Type: research
Acknowledgement to Referees
(Source: Targeted Oncology)
Source: Targeted Oncology - November 7, 2023 Category: Cancer & Oncology Source Type: research
Systematic Literature Review of the Prevalence and Prognostic Value of Delta-Like Ligand 3 Protein Expression in Small Cell Lung Cancer
ConclusionsThere is a high prevalence of DLL3 expression in SCLC. Further research and analytical methods may help to characterize different populations of patients with SCLC based on DLL3 expression. While no significant prognostic factor in the included studies was identified, additional cohort studies using standardized methodology, with longer follow-up, are needed to better characterize any potential differences in patient survival or response by DLL3 expression level in SCLC. (Source: Targeted Oncology)
Source: Targeted Oncology - November 6, 2023 Category: Cancer & Oncology Source Type: research
Histo-Molecular Factors of Response to Combined Chemotherapy and Immunotherapy in Non-Small Cell Lung Cancers
ConclusionThis study suggests that the efficacy of combining pembrolizumab with pemetrexed and platinum-based chemotherapy differs according to the histo-molecular biomarkers, which may help to identify patients liable to benefit from CIT. (Source: Targeted Oncology)
Source: Targeted Oncology - November 3, 2023 Category: Cancer & Oncology Source Type: research
Chemoimmunotherapy Versus Pembrolizumab as a First-Line Treatment for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression: Focus on the Role of Performance Status
ConclusionsIn patients with NSCLC exhibiting poor PS and high PD-L1 expression, ICI plus chemotherapy did not confer PFS or OS benefit compared with pembrolizumab monotherapy. (Source: Targeted Oncology)
Source: Targeted Oncology - October 30, 2023 Category: Cancer & Oncology Source Type: research
